";s:4:"text";s:4098:" Allen GS. 195. Each liquid filled c… Roine RO, Kaste M, Kinnunen A et al. 229. Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results. 83. 207. Hinkle PM, Jackson AE, Thompson TM et al. 192. Brandt L, Saveland H, Ljunggren B et al. Resorptie: oraal vrijwel volledig. 149. Select one or more newsletters to continue. Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage: clinical results of a multicenter study. It has a molecular weight of 418.5 and a molecular formula of C21H26N2O7. Walley TJ, Woods KL, Barnett DB. 189. Pellettieri L, Bolander H, C et al. 194. 197. Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Seiler RW, Reulen HJ, Huber P et al. Braunwald E, Isselbacher KJ, Petersdorf RG et al, eds. 51.
156. The 1,4-dihydropyridine receptor: a regulatory component of the Ca49. Kazner E, Sprung C, Adelt D et al. Gelmers HJ. Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage. Tietze K, Schwartz ML, Vlasses PH. Product Category Ingredients NDC Form Quantity Route Marketing Label; Nimodipine: HUMAN PRESCRIPTION DRUG LABEL: 1: 0904-6566: CAPSULE, LIQUID FILLED: 30 mg: ORAL: ANDA
Das G. Fundamentals of calcium channel blockers. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Administration of smaller dose of nimodipine (0.01 mg/kg) also produced dilation of the pial vessels, although the effect was less remarkable in the smaller arteries. DuCharme DW, Freyburger WA, Graham BE et al. FDA alert for healthcare professionals regarding potential serious medication administration errors from parenteral use of nimodipine capsules (marketed as Nimotop). Nimodipine facilitates associative learning in aging rabbits. 177. Dihydropyridine modulators of voltage-sensitive Ca202. 142. 24. van den Kerkhoff W, Drewes LR. Stuttgart: Schattauer Verlag; 1985:445-50.237. The comparative CNS pharmacology of nimodipine in humans. Heikkinen ER, Koivukangas J. (German; with English abstract.) 134. 160. %PDF-1.5
Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study. 1991 Jan;38(1):75-89. doi: 10.1007/BF03009168. Huyghens LP, Buylaert WA, Corne L et al.
Draski LJ, Johnston JE, Isaacson RL. 225.
Torrealba G, Sharp A, Soto B. Nimodipine-treated subarachnoid hemorrhage associated with acute pseudo-obstruction of the colon. 75.
Gelmers HJ, Hennerici M. Effect of nimodipine on acute ischemic stroke: pooled results from five randomized trials. Tsuruo T, Iida H, Nojiri M et al.
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.44 841.68] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>>
Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker originally developed for the treatment of high blood pressure. Allen GS. Adams RD, Martin JB. Auer LM, Suzuki A, Yasui N et al. Cerebrovascular diseases.
Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. 28. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation: a placebo-controlled, double-blind, randomized trial. In: Betz E, Deck K, Hoffmeister F, eds. Ziegler R, Horstmann R, Wingender W et al. 1987 Nov;34(5):578-98. doi: 10.2165/00003495-198734050-00005.Drugs. Nimodipine in acute ischemic stroke. Onoda JM, Sloane BF, Honn KV. Philadelphia: Taylor and Francis; 1985:259-62.199. 48. Stuttgart: Schattauer Verlag; 1985:185-202.213. 39. 227. Hess P, Lansman JB, Tsien RW.